Sandhill Capital Partners LLC Sells 10,601 Shares of Pfizer Inc. (NYSE:PFE)

Sandhill Capital Partners LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 9.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 97,032 shares of the biopharmaceutical company’s stock after selling 10,601 shares during the period. Sandhill Capital Partners LLC’s holdings in Pfizer were worth $2,794,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. lifted its stake in shares of Pfizer by 40.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after buying an additional 1,365,295 shares during the period. LifePlan Financial LLC bought a new stake in shares of Pfizer in the fourth quarter valued at about $255,000. Brookstone Capital Management lifted its stake in shares of Pfizer by 88.5% in the third quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock valued at $14,109,000 after buying an additional 212,369 shares during the period. ETF Store Inc. lifted its stake in shares of Pfizer by 12.0% in the third quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock valued at $214,000 after buying an additional 727 shares during the period. Finally, KLCM Advisors Inc. lifted its stake in shares of Pfizer by 75.0% in the fourth quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock valued at $5,004,000 after buying an additional 74,487 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently issued reports on PFE. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research report on Thursday, January 4th. Finally, Guggenheim initiated coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. Eleven research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $36.33.

Pfizer Trading Down 3.8 %

PFE stock traded down $1.01 during midday trading on Thursday, reaching $25.26. The company’s stock had a trading volume of 47,041,425 shares, compared to its average volume of 41,958,969. Pfizer Inc. has a 52 week low of $25.23 and a 52 week high of $40.37. The stock has a market cap of $143.04 billion, a PE ratio of 70.17, a price-to-earnings-growth ratio of 1.19 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The business’s 50-day simple moving average is $27.05 and its 200-day simple moving average is $28.50.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. During the same period last year, the firm earned $1.14 earnings per share. The business’s revenue for the quarter was down 41.3% on a year-over-year basis. As a group, sell-side analysts expect that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a dividend of $0.42 per share. The ex-dividend date is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.65%. Pfizer’s dividend payout ratio is 466.67%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.